Transgene Biotek share price
High risk
You have to be logged in to add this to Watchlist.- ₹3.86(1.85%)April 17, 2025 15:15:00 PM IST
- NSE
- BSE
- Vol : 17.10K (NSE + BSE)Last 20 day avg : 48.73 K
Transgene Biotek is trading 1.85% upper at Rs 3.86 as compared to its last closing price. Transgene Biotek has been trading in the price range of 3.86 & 3.79. Transgene Biotek has given -43.48% in this year & 7.22% in the last 5 days. The company posted a net profit of -0.09 Crores in its last quarter.Listed peers of Transgene Biotek include Vineet Laboratories (-3.58%), Veerhealth Care (3.22%), Transgene Biotek (1.85%).The Mutual Fund holding in Transgene Biotek was at -% in . The MF holding has - from the last quarter. The FII holding in Transgene Biotek was at -% in . The FII holding has - from the last quarter.
- Overview
- Financials
- Forecast
- Technical Analysis
- Peers
- Shareholding
- About the company
- FAQ
Overview
- 1 D
- 5 D
- 1 M
- 3 M
- 6 M
- 1 Y
- 5 Y
- MAX
Key Metrics
Updated on Apr 18, 2025, 08:21 PM UTC
- Dividend YieldLower than industry0.00Annual dividends as a percentage of the stock price.
- P/BLower than historical values2.73The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.
- P/EHigher than historical values0.00Price-to-earnings ratio based on trailing 12-month earnings
- BetaHigh volatility1.67Beta measures a stock's volatility compared to the overall market. A beta > 1 indicates higher volatility than the market.
- Debt To EquityHigher than industry1.31The debt-to-equity ratio, indicating a company's financial leverage.
- PEG Ratio-The PEG ratio evaluates a stock's valuation by comparing its P/E ratio to its earnings growth rate. A lower PEG suggests better value relative to growth
Price range
Day Range
|
| ||||
52 week range
|
| ||||
Transgene Biotek Financials
Financials
View allFinancials include key reports like the Profit & Loss Statement (P&L), Balance Sheet, and Cash Flow Statement, providing insights into a company's performance, financial health, and liquidity
- Income
- Balance Sheet
- Cash Flow
Loading...
Units in the chart are in crores
Insights
- Financial
- Valuation
Company is not profitable
The company's revenue grew in December quarter by 70.00% from Rs 0.08 crore to Rs 0.05 crore, year-on-year- The company has reduced its December quarter loss by 25.27% from Rs 0.12 crore to Rs 0.09 crore, year-on-year
- The debt to equity of the company is higher than the industry median
- Earnings are insufficient to cover the interest expenses on outstanding debt
Transgene Biotek Technical Analysis
Pivot Level - classic
Key price levels (support and resistance) calculated using the previous day's high, low, and close, aiding in technical analysis and trading decisions
- R1
- 3.73
- R2
- 4.10
- R3
- 4.31
Pivot3.52
- S1
- 3.15
- S2
- 2.94
- S3
- 2.57
Short Term
Considers price movement over the last 1-2 weeks
Not Available
Long Term
Considers price movement over the last 6 months
Not Available
- Very Bearish
- Bearish
- Neutral
- Very Bullish
- Bullish
Trends unavailable at the moment.
Transgene Biotek Peers
Return Comparison
Peers Comparison
Names | Technical rating | Price | %Change | Market Cap | P/E | P/B | Dividend Yield | Debt to Equity |
|---|---|---|---|---|---|---|---|---|
| Vineet Laboratories | Bearish | 32.60 | -3.58 | 30.05 | 29.79 | 0.88 | - | 11.19 |
| Veerhealth Care | Neutral | 15.70 | 3.22 | 31.40 | 74.90 | 1.39 | - | - |
| Transgene Biotek | Neutral | 3.86 | 1.85 | 25.39 | - | 2.68 | - | 47.41 |
| Aryavan Enterprise | Neutral | 40.67 | 4.82 | 24.76 | 54.65 | 4.54 | - | - |
| Zenith Health Care | Neutral | 4.90 | 1.87 | 26.33 | 127.01 | 3.52 | - | - |
Transgene Biotek Shareholding
View AllShareholding Pattern
Breakdown of a company's ownership structure, showing stakes held by Promoters, Mutual Funds, FII(s) & Others.
Shareholding pattern for Transgene Biotek is currently unavailable
Please check back later.
Shareholding Insights
- Promoter(s) does not have a high stake in the company
- FIIs are not invested in this company
- Mutual Funds are not invested in this company.
Transgene Biotek Corporate Actions
View all- Board Meetings
- AGM
- Dividends
- Bonus
- Split
- Rights
| Meeting Date | Purpose |
|---|---|
| 2025-01-24 | Quarterly Results |
| 2024-11-12 | Quarterly Results & A.G.M. |
| 2024-08-10 | Quarterly Results |
| 2024-05-30 | Audited Results |
| 2024-02-14 | Quarterly Results |
About the company Transgene Biotek
- IndustryBiotechnology & Drugs
- ISININE773D01018
- BSE Code526139
- NSE Code
Transgene Biotek Limited is an India-based biotechnology company. It is engaged in the research and development of vaccines, oncology, and new drug delivery technologies. Its portfolio of products includes oncology, autoimmunity, drug delivery and biogenetics. The Company offers TrabiAAV, which is a platform for the delivery of micro-ribonucleic acids (miRNAs), short hairpin RNA (ShRNAs), immunogens developing clinical significance in gene therapy and CRISPR/cas 9 technologies. Its monoclonal antibody therapy is the use of monoclonal antibodies to specifically bind to target cells. Its TrabiORAL drug is focused on delivering proteins and peptides orally for a variety of human diseases. Its TBL-1203 drug is used to strengthen cell-mediated immunity and complete the elimination of the human immunodeficiency virus (HIV), without any need for retroviral drug therapy. Its Tacrolimus drug suppresses the immune system and is mainly used to prevent rejection of transplanted organs.
Transgene Biotek Share Price FAQs
Transgene Biotek is trading at 3.86 as on Thu Apr 17 2025 09:45:00. This is 1.85% upper as compared to its previous closing price of 3.79.
The market capitalization of Transgene Biotek is 25.39 Cr as on Thu Apr 17 2025 09:45:00.
The 52 wk high for Transgene Biotek is 10.84 whereas the 52 wk low is 3.22
Transgene Biotek can be analyzed on the following key metrics -
- TTM P/E:
- Sector P/E: 41.24
- Dividend Yield: 0.00%
- D/E ratio: -
Transgene Biotek reported a net profit of -0.66 Cr in 2024.
Quick Links